Maree Smith

Last updated

Maree Therese Smith is an Australian researcher, inventor and innovator based at the University of Queensland and an Emeritus Professor. She is executive director of the Centre for Integrated Preclinical Drug Development, and TetraQ (a drug testing facility), head of the Pain Research Group in the UQ School of Pharmacy, and the inventor and developer of a potential novel treatment for chronic pain, EMA401. [1] [2]

Smith received a 2012 Life Sciences Queensland Industry Award for Excellence, [3] the 2015 Johnson & Johnson Innovation Industry Excellence Award for biotech industry leadership, [4] and the 2016 Australian Academy of Technological Sciences and Engineering Clunies Ross Award for contributions to the application of technology for the benefit of Australia. [5] She was elected a Fellow of the Australian Academy of Health and Medical Sciences in 2015. [6] She was the President of the Australian Pain Relief Association between 2014 and 2016.

Selected Publications

Related Research Articles

<span class="mw-page-title-main">Analgesic</span> Drugs used to achieve relief from pain

An analgesic drug, also called simply an analgesic, antalgic, pain reliever, or painkiller, is any member of the group of drugs used for pain management. Analgesics are conceptually distinct from anesthetics, which temporarily reduce, and in some instances eliminate, sensation, although analgesia and anesthesia are neurophysiologically overlapping and thus various drugs have both analgesic and anesthetic effects.

<span class="mw-page-title-main">Hydrocodone</span> Opioid drug used in pain relief

Hydrocodone, also known as dihydrocodeinone, is a semi-synthetic opioid used to treat pain and as a cough suppressant. It is taken by mouth. Typically it is dispensed as the combination acetaminophen/hydrocodone or ibuprofen/hydrocodone for pain severe enough to require an opioid and in combination with homatropine methylbromide to relieve cough. It is also available by itself in a long-acting form sold under the brand name Zohydro ER, among others, to treat severe pain of a prolonged duration. Hydrocodone is a controlled drug: in the United States a Schedule II Controlled Substance.

<span class="mw-page-title-main">Ketoprofen</span> NSAID analgesic medication

Ketoprofen is one of the propionic acid class of nonsteroidal anti-inflammatory drugs (NSAID) with analgesic and antipyretic effects. It acts by inhibiting the body's production of prostaglandin.

<span class="mw-page-title-main">Oxycodone</span> Opioid medication

Oxycodone, sold under the brand name Roxicodone and OxyContin among others, is a semi-synthetic opioid used medically for treatment of moderate to severe pain. It is highly addictive and is a commonly abused drug. It is usually taken by mouth, and is available in immediate-release and controlled-release formulations. Onset of pain relief typically begins within fifteen minutes and lasts for up to six hours with the immediate-release formulation. In the United Kingdom, it is available by injection. Combination products are also available with paracetamol (acetaminophen), ibuprofen, naloxone, naltrexone, and aspirin.

<span class="mw-page-title-main">Ibuprofen</span> Medication treating pain, fever, and inflammation

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that is used to relieve pain, fever, and inflammation. This includes painful menstrual periods, migraines, and rheumatoid arthritis. It may also be used to close a patent ductus arteriosus in a premature baby. It can be taken orally or intravenously. It typically begins working within an hour.

<span class="mw-page-title-main">University of Queensland</span> Public research university in Brisbane, Australia

The University of Queensland is a public research university located primarily in Brisbane, the capital city of the Australian state of Queensland. Founded in 1909 by the Queensland parliament, UQ is one of the six sandstone universities, an informal designation of the oldest university in each state. UQ is also a founding member of edX, Australia's leading Group of Eight and the international research-intensive Association of Pacific Rim Universities.

<span class="mw-page-title-main">Captopril</span> Antihypertensive drug of the ACE inhibitor class

Captopril, sold under the brand name Capoten among others, is an angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and some types of congestive heart failure. Captopril was the first oral ACE inhibitor found for the treatment of hypertension. It does not cause fatigue as associated with beta-blockers. Due to the adverse drug event of causing hyperkalemia, as seen with most ACE Inhibitors, the medication is usually paired with a diuretic.

<span class="mw-page-title-main">Amlodipine</span> Medication against high blood pressure

Amlodipine, sold under the brand name Norvasc among others, is a calcium channel blocker medication used to treat high blood pressure, coronary artery disease (CAD) and variant angina. It is taken orally.

<span class="mw-page-title-main">Dihydromorphine</span> Semi-synthetic opioid analgesic drug

Dihydromorphine is a semi-synthetic opioid structurally related to and derived from morphine. The 7,8-double bond in morphine is reduced to a single bond to get dihydromorphine. Dihydromorphine is a moderately strong analgesic and is used clinically in the treatment of pain and also is an active metabolite of the analgesic opioid drug dihydrocodeine. Dihydromorphine occurs in trace quantities in assays of opium on occasion, as does dihydrocodeine, dihydrothebaine, tetrahydrothebaine, etc. The process for manufacturing dihydromorphine from morphine for pharmaceutical use was developed in Germany in the late 19th century, with the synthesis being published in 1900 and the drug introduced clinically as Paramorfan shortly thereafter. A high-yield synthesis from tetrahydrothebaine was later developed.

<span class="mw-page-title-main">Dextromoramide</span> Opioid analgesic drug

Dextromoramide is a powerful opioid analgesic approximately three times more potent than morphine but shorter acting. It is subject to drug prohibition regimes, both internationally through UN treaties and by the criminal law of individual nations, and is usually prescribed only in the Netherlands.

<span class="mw-page-title-main">Ian Frazer</span> Scottish-born Australian immunologist

Ian Hector Frazer is a Scottish-born Australian immunologist, the founding CEO and Director of Research of the Translational Research Institute (Australia). Frazer and Jian Zhou developed and patented the basic technology behind the HPV vaccine against cervical cancer at the University of Queensland. Researchers at the National Cancer Institute, Georgetown University, and University of Rochester also contributed to the further development of the cervical cancer vaccine in parallel.

An equianalgesic chart is a conversion chart that lists equivalent doses of analgesics. Equianalgesic charts are used for calculation of an equivalent dose between different analgesics. Tables of this general type are also available for NSAIDs, benzodiazepines, depressants, stimulants, anticholinergics and others.

Translational research is research aimed at translating (converting) results in basic research into results that directly benefit humans. The term is used in science and technology, especially in biology and medical science. As such, translational research forms a subset of applied research.

Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors (GPCR) biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.

<span class="mw-page-title-main">EMA401</span> Chemical compound

EMA401 is a drug under development for the treatment of peripheral neuropathic pain. Trials were discontinued in 2015, with new trials scheduled to begin March, 2018. It was initially established as a potential drug option for patients suffering pain caused by postherpetic neuralgia. It may also be useful for treating various types of chronic neuropathic pain EMA401 has shown efficacy in preclinical models of shingles, diabetes, osteoarthritis, HIV and chemotherapy. EMA401 is a competitive antagonist of angiotensin II type 2 receptor (AT2R) being developed by the Australian biotechnology company Spinifex Pharmaceuticals. EMA401 target angiotensin II type 2 receptors, which may have importance for painful sensitisation.

<span class="mw-page-title-main">Jennifer L. Martin</span> Australian molecular biologist

Professor Jennifer Louise "Jenny" Martin is an Australian scientist and academic. She was the Deputy Vice-Chancellor at the University of Wollongong, in New South Wales from 2019-2022. She is a former director of the Griffith Institute for Drug Discovery at Griffith University. and a former Australian Research Council Laureate Fellow at the Institute for Molecular Bioscience, University of Queensland. Martin is Professor Emerita at the University of Queensland and adjunct professor at Griffith University. Her research expertise encompasses structural biology, protein crystallography, protein interactions and their applications in drug design and discovery.

<span class="mw-page-title-main">Endomorphin-1</span> Chemical compound

Endomorphin-1 (EM-1) (amino acid sequence Tyr-Pro-Trp-Phe-NH2) is an endogenous opioid peptide and one of the two endomorphins. It is a high affinity, highly selective agonist of the μ-opioid receptor, and along with endomorphin-2 (EM-2), has been proposed to be the actual endogenous ligand of the μ-receptor. EM-1 produces analgesia in animals and is equipotent with morphine in this regard. The gene encoding for EM-1 has not yet been identified, and it has been suggested that endomorphins could be synthesized by an enzymatic, non-ribosomal mechanism.

<span class="mw-page-title-main">Fakhreddin Jamali</span> Iranian-Canadian pharmacist

Fakhreddin Jamali is an Iranian-Canadian professor emeritus of pharmacy and pharmaceutical sciences at the University of Alberta. He is the founding president of the Canadian Society for Pharmaceutical Sciences, and the editor-in-chief of Journal of Pharmacy and Pharmaceutical Sciences.

<span class="mw-page-title-main">Mitragynine</span> Opioid analgesic compound

Mitragynine is an indole-based alkaloid and the most abundant active alkaloid in the Southeast Asian plant Mitragyna speciosa, commonly known as kratom. The total alkaloid concentration in dried leaves ranges from 0.5 to 1.5%. In Thai varieties, mitragynine is the most abundant component, while 7-hydroxymitragynine is a minor constituent. In Malaysian kratom varieties, mitragynine is present at lower concentration. Such preparations are orally consumed and typically involve dried kratom leaves which are brewed into tea or ground and placed into capsules. Mitragynine consumption for medicinal and recreational purposes dates back centuries, although early use was primarily limited to Southeast Asian countries such as Indonesia and Thailand, where the plant grows indigenously. Recently, mitragynine use has spread throughout Europe and the Americas as both a recreational and medicinal drug. While research into the effects of kratom have begun to emerge, investigations on the active compound mitragynine are less common.

Paul Edward Rolan is an Australian physician, medical researcher, academic, and public health advocate. He specializes in the management of chronic pain and headache, and development of novel treatments.

References

  1. ↑ "Professor Maree Smith FTSE - School of Pharmacy - The University of Queensland, Australia". Uq.edu.au. Archived from the original on 24 July 2016. Retrieved 20 June 2016.
  2. ↑ "University of Queensland Professor Maree Smith Awarded Prestigious Clunies Ross Award". The Daily Telegraph . Retrieved 20 June 2016.
  3. ↑ "Prof. Maree Smith receives Life Sciences award - School of Pharmacy - The University of Queensland, Australia". Uq.edu.au. 24 March 2014. Archived from the original on 13 June 2016. Retrieved 20 June 2016.
  4. ↑ "UQ pain drug inventor and $200m start-up win national awards - UQ News - The University of Queensland, Australia". Uq.edu.au. Retrieved 20 June 2016.
  5. ↑ "Prestigious award for UQ superstar scientist - UQ News - The University of Queensland, Australia". Uq.edu.au. Retrieved 20 June 2016.
  6. ↑ "Fellowship of the Australian Academy of Health and Medical Sciences" (PDF). Australian Academy of Health and Medical Sciences. October 2021. Retrieved 11 March 2022.
  7. ↑ Shepherd, Andrew J.; Rice, Andrew SC.; Smith, Maree T. (1 December 2023). "Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation". Current Opinion in Pharmacology. 73: 102415. doi: 10.1016/j.coph.2023.102415 . ISSN   1471-4892. PMID   38041933.
  8. ↑ Imam, Mohammad Zafar; Ghassabian, Sussan; Kuo, Andy; Cai, Yunxin; Qin, Yajuan; Li, Tingyou; Smith, Maree T. (1 July 2023). "In Vitro Assessment of the Metabolic Stability of Two Novel Endomorphin-2 Analogs, CYX-5 and CYX-6, in Rat Liver Microsomes". European Journal of Drug Metabolism and Pharmacokinetics. 48 (4): 463–466. doi:10.1007/s13318-023-00828-6. ISSN   2107-0180. PMID   37171777.
  9. ↑ Smith, Maree T. (November 2022). "Nonopioid analgesics discovery and the Valley of Death: EMA401 from concept to clinical trial". PAIN. 163 (S1): S15–S28. doi:10.1097/j.pain.0000000000002675. ISSN   0304-3959. PMC   10578428 . PMID   35984369.
  10. ↑ Smith, A. E.; Muralidharan, A.; Smith, M. T. (18 October 2022). "Prostate cancer induced bone pain: pathobiology, current treatments and pain responses from recent clinical trials". Discover Oncology. 13 (1): 108. doi:10.1007/s12672-022-00569-z. ISSN   2730-6011. PMC   9579264 . PMID   36258057.
  11. ↑ https://jpharmsci.org/article/S0022-3549(18)30629-4/abstract.{{cite web}}: Missing or empty |title= (help)
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.